This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Diabetes-Drug Makers Face FDA Hurdle

"An FDA mandate for cardiovascular screening trials prior to approval for all novel diabetes drugs will slow development and increase costs (potentially making it uneconomical for some and pushing incremental capital in other directions)" wrote Morgan Stanley's Harr.

If a company has a diabetes drug in phase II studies where the increased risk of heart attack or stroke cannot be ruled in or out, the FDA may require that company to conduct a much larger and longer phase III clinical trial to definitively rule out any such heart risk. Such a trial could add years and tens of millions of dollars to the development costs, Harr writes in his note.

For other companies, the FDA may grant conditional approval of a diabetes drug but still require a post-approval cardiovascular risk study. Such an expense would reduce the near-term profit margin on any new diabetes drug, Harr says.

Mads Krogsgaard Thomsen, chief science officer of Novo Nordisk, said he expects a discussion about a post-approval cardiovascular commitment to be discussed at the April advisory panel meeting.

Merck (MRK) recently announced that it would conduct a post-approval study of its diabetes drug Januvia in 14,000 diabetics specifically to look for increased heart safety risks.

Senior Wrtiter Adam Feuerstein contributed to this report.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BMY $67.67 2.27%
AZN $64.64 1.46%
GSK $42.14 1.18%
INCY $104.45 0.23%
NVO $55.44 1.24%

Markets

DOW 17,757.91 +138.40 0.79%
S&P 500 2,077.42 +14.31 0.69%
NASDAQ 5,013.1230 +26.2560 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs